Application 077908

Type
ANDA
Sponsor
HOSPIRA

Application Products#

Product, Drug, Ingredient table
ProductDrugIngredientFormStrengthReference drugReference standard
001PROPOFOLPROPOFOLINJECTABLE;INJECTION10MG/MLNoNo

Orange Book products#

Application-product, Trade name, Ingredient table
Application-productTrade nameIngredientStrengthDosage form / routeTE codesRLD / RSApproval date
A077908-001PROPOFOLPROPOFOL10MG/MLINJECTABLE / INJECTIONAB2006-03-17

Therapeutic equivalence codes#

Application-product, TE code table
Application-productTE code
A077908-001AB

openFDA label cross-check#

Cross-check layer: openFDA label JSON enriches search and identifies hydration gaps. The DailyMed Structured Product Label remains the canonical label presentation on FDA.report.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
PROPOFOLPROPOFOLHospira, Inc.28d7ba00-f824-4e55-139a-03f509c099db2025-12-17Warnings, Adverse reactionsExact identifier
PROPOFOLPROPOFOLHF Acquisition Co LLC, DBA HealthFirst99af9e0a-c268-84ca-e053-2a95a90a0a3e2025-01-08Warnings, Adverse reactionsExact identifier
PROPOFOLPROPOFOLHF Acquisition Co LLC, DBA HealthFirst99c8438a-2b3c-796e-e053-2a95a90a02002025-01-08Warnings, Adverse reactionsExact identifier
PROPOFOLPROPOFOLHF Acquisition Co LLC, DBA HealthFirst7b9599e0-5bad-742d-e053-2991aa0aee972022-12-09Warnings, Adverse reactionsExact identifier

Warnings cross-check#

openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.

warnings and cautions

5 WARNINGS AND PRECAUTIONS Hypersensitivity Reactions : Serious and sometimes fatal reactions ( 5.1 ) Microbial Contamination : Strict aseptic technique must be maintained during handling. Propofol injectable emulsion vials are never to be accessed more than once or used on more than one person. Administration should commence promptly and be completed within 12 hours after the vial has been opened. Discard unused drug product. Do not use if contamination is suspected ( 5.2 ) Cardiovascular Depression : Cases of bradycardia, asystole, and cardiac arrest have been reported. Pediatric patients are susceptible to this effect, particularly when fentanyl is given concomitantly ( 5.4 ) 5.1 Anaphylactic and Anaphylactoid Reactions Use of propofol injectable emulsion has been associated with both fatal and life threatening anaphylactic and anaphylactoid reactions. Clinical features of anaphylaxis, including angioedema, bronchospasm, erythema, and hypotension, occur rarely following propofol injectable emulsion administration. 5.2 Risks of Microbial Contamination Strict aseptic technique must always be maintained during handling. Propofol injectable emulsion is a single-dose parenteral product (single patient infusion vial) which contains benzyl alcohol 1.5 mg/mL and sodium benzoate 0.7 mg/mL to inhibit the rate of growth of microorganisms, for up to 12 hours, in the event of accidental extrinsic contamination. However, propofol injectable emulsion can still support the growth of microorganisms, as it is not an antimicrobially preserved product under USP standards. Do not use if contamination is suspected. Discard unused drug product as directed within the required time limits. There have been reports in which failure to use aseptic technique when handling propofol injectable emulsion was associated with microbial contamination of the product and with fever, infection/sepsis, other life-threatening illness, and/or death. Propofol injectable emulsion vials are never to be accessed more than once or used on more than one person. There have been reports, in the literature and other public sources, of the transmission of bloodborne pathogens (such as Hepatitis B, Hepatitis C, and HIV) from unsafe injection practices, and of the use of propofol vials intended for single use on multiple persons. 5.3 Risks of Pediatric Neurotoxicity Published animal studies demonstrate th...

Adverse reactions cross-check#

openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.

adverse reactions

6 ADVERSE REACTIONS The following serious or otherwise important adverse reactions are discussed elsewhere in the labeling: • Hypersensitivity reaction [see Warnings and Precautions (5.1) ] • Hypotension and/or bradycardia [see Warnings and Precautions (5.4) ] • Propofol Infusion Syndrome [see Warnings and Precautions (5.9) ] In the description below, rates of the more common events represent US/Canadian clinical study results. Less frequent events are also derived from publications and marketing experience in over 8 million patients; there are insufficient data to support an accurate estimate of their incidence rates. These studies were conducted using a variety of premedicants, varying lengths of surgical/diagnostic procedures, and various other anesthetic/sedative agents. Most adverse events were mild and transient. Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. Anesthesia and MAC Sedation in Adults The following estimates of adverse events for propofol injectable emulsion include data from clinical trials in general anesthesia/MAC sedation (N=2,889 adult patients). The adverse events listed below as probably causally related are those events in which the actual incidence rate in patients treated with propofol injectable emulsion was greater than the comparator incidence rate in these trials. Therefore, incidence rates for anesthesia and MAC sedation in adults generally represent estimates of the percentage of clinical trial patients which appeared to have probable causal relationship. The adverse experience profile from reports of 150 patients in the MAC sedation clinical trials is similar to the profile established with propofol injectable emulsion during anesthesia (see Table 2 below). During MAC sedation clinical trials, significant respiratory events included cough, upper airway obstruction, apnea, hypoventilation, and dyspnea. Anesthesia in Pediatric Patients Generally, the adverse experience profile from reports of 506 propofol injectable emulsion pediatric patients from 6 days through 16 years of age in the US/Canadian anesthesia clinical trials is similar to the profile established with propofol injectab...

adverse reactions table

Table 2. Treatment Emergent Adverse Events Observed from Clinical TrialsAnesthesia/MAC SedationICU SedationBody as a Whole:Anaphylaxis/Anaphylactoid reaction perinatal disorder, tachycardia, bigeminy, bradycardia, premature ventricular contractions, hemorrhage, ECG abnormal arrhythmia atrial, fever, extremities pain, anticholinergic syndrome, asthenia, awareness, chest pain, extremities pain, fever, increased drug effect, neck rigidity/stiffness, trunk painFever, sepsis, trunk pain, whole body weaknessCardiovascular:Premature atrial contractions Syncope, hypotension [see also Clinical Pharmacology (12)], tachycardia Nodal, arrhythmia Bradycardia, arrhythmia, atrial fibrillation, atrioventricular heart block, bigeminy, bleeding, bundle branch block, cardiac arrest, ECG abnormal, edema, extrasystole, heart block, hypertension, myocardial infarction, myocardial ischemia, premature ventricular contractions, ST segment depression, supraventricular tachycardia, tachycardia, ventricular fibrillationBradycardia, decreased cardiac output, arrhythmia, atrial fibrillation, bigeminy, cardiac arrest, extrasystole, right heart failure, ventricular tachycardiaCentral Nervous System:Hypertonia/Dystonia, paresthesia, movement, abnormal dreams, agitation, amorous behavior, anxiety, bucking/jerking/thrashing, chills/shivering/clonic/myoclonic movement, combativeness, confusion, delirium, depression, dizziness, emotional lability, euphoria, fatigue, hallucinations, headache, hypotonia, hysteria, insomnia, moaning, neuropathy, opisthotonos, rigidity, seizures, somnolence, tremor, twitchingAgitation, hypotension, chills/shivering, intracranial hypertension, seizures, somnolence, thinking abnormalDigestive:Hypersalivation, nausea, cramping, diarrhea, dry mouth, enlarged parotid, nausea, swallowing, vomitingIleus, liver function abnormalHemic/Lymphatic:Leukocytosis, coagulation disorderInjection Site:Phlebitis, pruritus, burning/stinging or pain, hives/itching, redness/discolorationMetabolic/Nutritional:hypomagnesemia, hyperkalemia, hyperlipemiaBUN increased, creatinine increased, dehydration, hyperglycemia, metabolic acidosis, osmolality increased, hyperlipemiaMusculoskeletal:MyalgiaNervous:Dizziness, agitation, chills, somnolence DeliriumRespiratory:Wheezing, cough, laryngospasm, hypoxia, apnea, bronchospasm, burning in throat, dyspnea, hiccough, hyperventilation, hypoventilat...

NDC Listings For This Application#

NDC, Name, Nonproprietary name table
NDCNameNonproprietary nameLabelerMarketing categoryStatus
0409-4699PROPOFOLPROPOFOLHospira, Inc.ANDACurrent
0409-4699PROPOFOLPROPOFOLHospira, Inc.ANDACurrent
0409-4699PROPOFOLPROPOFOLHospira, Inc.ANDACurrent
0409-4699PROPOFOLPROPOFOLHospira, Inc.ANDACurrent
0409-4699PROPOFOLPROPOFOLHospira, Inc.ANDACurrent
0409-4699PROPOFOLPROPOFOLHospira, Inc.ANDACurrent
0409-6010PROPOFOLPROPOFOLHospira, Inc.ANDACurrent
51662-1293PROPOFOLPROPOFOLHF Acquisition Co LLC, DBA HealthFirstANDACurrent
51662-1293PROPOFOLPROPOFOLHF Acquisition Co LLC, DBA HealthFirstANDACurrent
51662-1293PROPOFOLPROPOFOLHF Acquisition Co LLC, DBA HealthFirstANDACurrent
51662-1293PROPOFOLPROPOFOLHF Acquisition Co LLC, DBA HealthFirstANDACurrent
51662-1470PROPOFOLPROPOFOLHF Acquisition Co LLC, DBA HealthFirstANDACurrent
51662-1470PROPOFOLPROPOFOLHF Acquisition Co LLC, DBA HealthFirstANDACurrent
51662-1471PROPOFOLPROPOFOLHF Acquisition Co LLC, DBA HealthFirstANDACurrent
51662-1471PROPOFOLPROPOFOLHF Acquisition Co LLC, DBA HealthFirstANDACurrent
52584-699PropofolPropofolGeneral Injectables and Vaccines, IncANDACurrent
52584-699PropofolPropofolGeneral Injectables and Vaccines, IncANDACurrent
52584-699PropofolPropofolGeneral Injectables and Vaccines, IncANDACurrent

Documents#

Document, Submission type, Date table
DocumentSubmission typeDate
43132ORIG2012-06-22
44367ORIG2007-06-18